Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
The current price of STTK is $6.25 USD — it has decreased by -2.8% in the past 24 hours. Watch Shattuck Labs stock price performance more closely on the chart.
What is Shattuck Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Shattuck Labs stocks are traded under the ticker STTK.
Is Shattuck Labs stock price growing?▼
STTK stock has fallen by -0.95% compared to the previous week, the month change is a +56.25% rise, over the last year Shattuck Labs has showed a +535.42% increase.
What is Shattuck Labs market cap?▼
Today Shattuck Labs has the market capitalization of 395.49M
When is the next Shattuck Labs earnings date?▼
Shattuck Labs is going to release the next earnings report on May 13, 2026.
What were Shattuck Labs earnings last quarter?▼
STTK earnings for the last quarter are -0.12 USD per share, whereas the estimation was -0.14 USD resulting in a +11.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Shattuck Labs revenue for the last year?▼
Shattuck Labs revenue for the last year amounts to 11.44M USD.
What is Shattuck Labs net income for the last year?▼
STTK net income for the last year is -150.82M USD.
How many employees does Shattuck Labs have?▼
As of April 02, 2026, the company has 44 employees.
In which sector is Shattuck Labs located?▼
Shattuck Labs operates in the Health Care sector.
When did Shattuck Labs complete a stock split?▼
The last stock split for Shattuck Labs was on December 06, 2016 with a ratio of 1:800.